Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has entered into a strategic partnership with the US Naval Medical Research Center (NMRC) to develop a promising new bacterial vaccine against enterotoxigenic Escherichia coli (ETEC). ETEC causes nearly 400,000 childhood deaths in the developing world each year and is the predominant cause of infectious gastroenteritis in travellers and deployed military personnel, according to the American Society of Tropical Medicine and Hygiene (ASTMH).
The core ETEC adhesin vaccine technology, developed by NMRC, was exclusively licensed to Sanofi Pasteur, along with a second technology that efficiently packages the adhesin with a toxoid vaccine component, co-developed by NMRC and the University of Colorado Denver. The cooperative research and development agreement was executed between Sanofi Pasteur and NMRC, inaugurating a joint research effort to be conducted over the next four years.
The World Health organization agrees with the ASTMH mortality estimate and adds that ETEC accounts for approximately 210 million episodes of diarrhoea annually. ETEC is the most common cause of bacterial diarrhoea leading to dehydration and shock when not treated promptly and effectively. Food-borne diseases, including travelers' diarrhoea, afflict 40 to 60 per cent of the 80 million individuals who travel from industrialized countries to lesser developed countries each year and have been a scourge of military operations throughout history.
"We have committed our technical expertise to expedite development of this vaccine for eventual licensure and sales worldwide," said Wayne Pisano, president and CEO of Sanofi Pasteur. "This multi-year project will provide a solid basis for launching clinical development. Furthermore," Pisano continued, "we believe that this vaccine has the potential to curtail the number and severity of food-borne illnesses due to ETEC, and it may also decrease the risk of post-infectious irritable bowel syndrome, which afflicts one in ten who experience travellers' diarrhoea."
According to the agreement, if the four-year pre-clinical research effort proves successful, it will serve as the basis for launching full-scale clinical development of a multivalent adhesin-based ETEC vaccine.